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Introduction: The initial prognostic assessment of patients with community-acquired pneu-
monia (CAP) has important clinical implications. We hypothesized that midregional proadreno-
medullin (MR-proADM) is a valuable test for the prediction of outcomes in patients with CAP.
Methods: We performed a systemic review of the literature and a meta-analysis to evaluate
the prognostic value of MR-proADM for short and long-term mortality in patients with CAP.
Results: Twelve studies were included in the systematic review. Elevated MR-proADM was asso-
ciated with an increase in short-term mortality (OR Z 6.8; 95% CI: 4.65e10.13; P
value < 0.001) and complications (ORZ 5.0; 95% CI: 3.86e6.49; P value < 0.001). The pooled
analysis of 4 studies showed an improvement in the discriminant ability by 8% (95% CI: 2%e14%)
when MR-proADM was added to CURB-65/CRB-65. Studies that reported long-term prognosis
indicated an increased risk of death in patients with elevated MR-proADM.
Conclusion: Elevated level of MR-proADM is significantly associated with both short-term mor-
tality and complications in patients with CAP. Studies also indicate that MR-proADM has prog-
nostic value for prediction of long-term mortality in these patients. The addition of MR-proADM
improves the discriminant ability of CURB-65/CRB-65.
ª 2014 Elsevier Ltd. All rights reserved.ulmonary, Critical Care and Sleep Disorders Medicine, 550 S. Jackson Street, ACB, A3R27, Louisville,
e.edu (R. Cavallazzi).
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One of the most challenging tasks clinicians face when
assessing patients with community-acquired pneumonia
(CAP) is to risk stratify them. The initial risk stratification
has important clinical implications. It is largely based on
the stratification that clinicians decide on the setting to
manage patients with CAP. To that end, clinicians have
relied mainly on clinical judgment and clinical prediction
rules.
In recent years, biomarkers have emerged that can help
with the prediction of outcomes in patients with CAP. One
that has been in the spotlight is midregional proa-
drenomedullin (MR-proADM), a peptide that was initially
identified in plasma of patients with septic shock at high
concentrations. MR-proADM is derived from the same pre-
cursor as adrenomedullin, which is a 52-amino acid peptide
with important hemodynamic effects [1].
Although adrenomedullin cannot be reliably measured in
the plasma due to its short half-life and physical properties,
an immunoluminometric assay has been developed for the
more stable MR-proADM [2]. The measurement of MR-
proADM can thus serve as a proxy for the production of
the more physiologically active adrenomedullin. Since the
development of the assay, a number of studies have re-
ported on the predictive value of MR-proADM in patients
with CAP [3e7]. We thought that an objective and criticalappraisal of these studies is timely. We hypothesized that
MR-proADM is a valuable test for the prediction of outcomes
in patients with CAP. The primary aim of our study is to
evaluate the literature on the prognostic value of MR-
proADM for short and long-term mortality in patients with
CAP. Secondary aims are to assess whether MR-proADM can
predict short-term complications in patients with CAP and
whether MR-proADM can improve the discriminant ability of
a risk score. We carried out a systematic review and meta-
analysis of the studies assessing MR-proADM in these
patients.Methods
Eligibility criteria
Studies that reported the prognostic value of MR-proADM
for short and long-term mortality or complications in pa-
tients with CAP were eligible for inclusion in this systematic
review.
Exclusion criteria
Studies were excluded if the patient population was not
composed solely of patients with CAP. We also excluded
studies with duplicate patient cohorts. However, when two
Midregional proadrenomedullin 1571studies using the same patient cohort reported on different
outcomes (e.g. different time ascertainment), they were
included in the systematic review but their data were not
pooled in the same meta-analysis.
Predictive variables
The main predictive variable was MR-proADM level. A
commercially available test has been developed for the
measurement of MR-proADM in the plasma (B.R.A.H.M.S
MR-proADM KRYPTOR). This test is performed via sandwich
immunoluminometric assay. Antibodies are employed
against the 45-92 MR-proADM. The initial report of the test
established that the lower detection limit was 0.08 nmol/L
[2]. We also analyzed the discriminant ability of the
confusion, urea, respiratory and blood pressure (CURB)
score. The CURB score is based on severity criteria for
pneumonia developed by the British Thoracic Society:
confusion, urea  7 mmol/l, respiratory rate  30/min, and
blood pressure  60 mmHg. An early study showed that the
presence of 2 of these criteria upon hospital admission is
highly sensitive for the prediction of death in patients with
CAP [8]. There are interactions of the CURB score such as
the CURB-65, which also relies on age  65 years as a cri-
terion and adds low systolic blood pressure (<90 mmHg) to
the blood pressure criterion, and CRB-65, which does not
take urea into account [9,10].
Outcomes
The primary outcome was short-term mortality. Studies
that reported mortality on <3 month follow-up or in-
hospital mortality were included in this category. If a
study reported the primary outcome in multiple time
points, we chose the one that most closely approximated to
30 days. Another primary outcome was long-term mortality.
Studies that reported mortality on follow-up of 3 months
were include in this category. The secondary outcome was
a composite of short-term complications. The latter
included death plus one or a combination of following
outcomes as reported in the primary studies: need for ICU
admission, need for mechanical ventilation, respiratory
failure, and other disease-specific complications.
Search
Two investigators (KEL and EAA) independently performed a
search in Pubmed and Embase through Feb/2013. For
Pubmed, the search strategy included the following:
(“Respiratory Tract Infections”[Mesh] OR “pneumonia”[All
Fields]) AND (“Pro-adrenomedullin”[All Fields] OR “adre-
nomedullin”[All Fields] OR “Proadrenomedullin”[All
Fields]). The Embase search strategy included the
following: (pneumonia.mp OR respiratory.mp) AND (adre-
nomedullin.mp OR proadrenomedullin.mp OR pro-
adrenomedullin.mp).
Risk of bias
We used the following items to assess risk of bias: de-
mographic characteristics, selection criteria, definition ofCAP, index test obtained early in the course of disease,
description of execution of index test, establishment of
test cutoff before analysis, pre-specified objectives, long-
term follow up, and absence of commercial funding. These
were derived from a number of documents [11e13].
Data extraction
Two investigators (KEL and EAA) independently extracted
data from the studies, and conflicts were resolved by a
third investigator (RC). We used a structured form to
extract data from the studies. Data extracted included
study setting and design, patient characteristics, study
objective, quality items, and numerical data. We extracted
the 4 cell values of a diagnostic 2  2 table for MR-proADM
prediction of outcomes.
We also abstracted the reported MR-proADM area under
the receiver operating characteristic curve (AUC) with
corresponding 95% CI for the prediction of short-term
mortality. In order to allow comparison of the discrimi-
nant ability with MR-proADM, we abstracted the AUC with
95% CI of the CURB-65 or CRB-65 as reported by the primary
studies. For the purpose of this review, we use both the
CURB-65 and the CRB-65 interchangeably. For the sake of
simplicity, we designate them risk score.
For long-term prognosis, we abstracted the reported
estimate (measure of association) providing information on
the predictive value of MR-proADM for mortality. We pref-
erentially abstracted the estimates that were adjusted for
severity of disease or clinical prediction rules.
Statistical analysis
We present the sensitivity and specificity of MR-proADM for
in-hospital mortality. If a study reported data based on
more than one threshold, we used data based on the
threshold that was established a priori. We summarize
these estimates in forest plots. We also provide pooled odds
ratios of MR-proADM for both short-term mortality and
complications.
In order to evaluate if MR-proADM provides additional
discriminant ability when combined with CURB-65 or CRB-
65, we calculated the ratio of risk score plus MR-proADM
over risk score. We obtained the standard error (SE) of the
ratio by calculating the SE of the log-AUC of risk score and
the SE of log-AUC of MR-proADM plus risk score. The SE of
the ratio was then obtained with a previously described
method [14]. The SE of the AUC reported in the primary
studies was derived from the 95% CI. When we were unable
to obtain the 95% CI from the primary studies or after
contact attempt with their authors, we calculated it by
estimating the AUC SE with the method proposed by Hanley
and McNeil [15]. We present pooled AUC ratio; a value
above one indicates that the combined risk score plus MR-
proADM provides better discriminant ability than the risk
score alone.
We performed meta-analysis using a random-effects
model [16]. This approach assumes that the effect esti-
mates vary among the studies. We evaluated heterogeneity
with a chi-squared test and the I2. We considered hetero-
geneity to be present with a P value <0.1, or when the I2
1572 R. Cavallazzi et al.was more than 30%. For the remainder of the analyses, we
considered a P value <0.05 statistically significant. We used
Stata 10 (StataCorp LP; College Station, TX) and Review
Manager 5.2 software [17] for statistical analysis.
For long-term mortality, we decided that meta-analysis
would not be appropriate given the heterogeneity in how
the data were reported. However, we abstracted the data
as stated above, and we appraise the evidence in the dis-
cussion section.
Results
Our search identified 213 citations. After removing dupli-
cates, we were left with 182 articles. Based on screening of
titles and abstracts, we exclude 160 citations. These were
excluded mostly because they were review articles or let-
ters to the editors or articles that clearly did not pertain to
the topic of this review. We fully reviewed 22 articles. Of
these, we excluded 10 articles. The reasons for exclusion
included different outcome [18], patient population not
exclusively composed of patients with CAP [19e23], and
duplicate cohorts [24e26]. An additional article was pre-
sent only in abstract form, which did not provide enough
data for extraction for our review [27]. We included 12
articles in this review (see Fig. 1) [4e7,28e34]. Table 1
shows the characteristics of the studies.
Primary outcomes
For short-term mortality, we pooled data from 9 studies,
which included a total population of 4201 patients (see
Fig. 2) [3e5,7,28,31e34]. There was significant increase in
short-term mortality with elevated MR-proADM (OR Z 6.8;Figure 1 Flow chart of the s95% CI: 4.65e10.13; P value < 0.001). There was no sig-
nificant heterogeneity (P value Z 0.187). The I2 value was
29%. However, the estimates of sensitivity and specificity
ranged substantially. Even within studies that used similar
thresholds of around 1.5e1.85, the sensitivity varied from
0.46 to 0.85. The specificity also varied within this set of
studies, ranging from 0.64 to 0.86 (see Fig. 3).
Five studies reported on long-term-mortality
[4,6,7,28,33]. They showed increased risk of mortality in
patients with elevated MR-proADM although in the study by
Huang et al. this effect was limited to patients with
Pneumonia Severity Index (PSI) classes IV/V [28]. We sum-
marize these studies in Table 2.
Pooled AUC ratio for the prediction of short-term
mortality
On its own, MR-proADM showed moderate to good discrim-
inant ability, ranging from 0.72 to 0.89 across 9 studies
[3e5,7,28,31e34]. Four studies reported the AUC for MR-
proADM, risk score, and risk score plus MR-proADM
[3,4,7,33]. The discriminant ability of MR-proADM on its
own, and together with the risk score in these 4 studies, is
shown in Table 3. The pooled ratio of risk score plus MR-
proADM over risk score was 1.08 (95% CI: 1.02e1.14; P
value Z 0.006; homogeneity test P value Z 0.8; I2
value Z 0%). Fig. 4 shows forest plot of the meta-analysis.
Short-term complications
For the composite outcome of short-term complications,
we pooled data from 5 studies (see Fig. 5) [3,4,29,30,34].
There was significant increase in short-term complicationearch process for studies.
Table 1 Characteristics of the studies included in this review.
Author, year Study setting Study design Patient
population
Patients,
n
Age, yr Male, % Aim Mortality, %
Christ-
Crain,2006 [5]
Switzerland,
2003e2005
Prospective
cohort
Adults with CAP
in the ED
302 69.6
(Mean)
61.9 Assessment of
prognostic
factors and
biomarkers in
CAP
12.6 (follow-
up; mean 6.9
weeks)
Huang, 2009 [28] US, 2001e2003 Prospective
cohort
Adults with CAP
in the ED
1653 65
(Mean)
52 Determine the
pattern and
prognostic role
of MR-proADM
in CAP
6.4 (30 days)
7.2 (48 days)
9.8 (90 days)
Kruger, 2010 [7] Germany Prospective
cohort
Adults with CAP 728 59
(Mean)
59 Validate the
predictive
value of
biomarkers in
CAP
2.5 (28 days)
5 (180 days)
Guertler,
2011 [6]*
Switzerland,
2006e2008
Prospective
cohort
Adults with CAP 877 73**
(Median)
58.4** Evaluate the
prognostic
value of PSI and
biomarkers in
CAP
17.3 (18
months)
Albrich,
2011 [3]*
Switzerland,
2006e2008
Prospective
cohort
Adults with CAP 925 73**
(Median)
57.5** Evaluate the
prognostic
value of
biomarkers in
lower
respiratory
tract infection
5.4 (30 days)
Bereciartua
Urbieta,
2011 [29]
Spain,
2008e2009
Prospective
cohort
Adults with CAP
admitted
through the ED
250 71.1
(Mean)
68.4 Evaluate if
biomarkers can
predict bad
outcomes in
patients with
CAP
8 (in-hospital)
Bello, 2012 [4] Spain Prospective
cohort
Adults with CAP
admitted
through the ED
228 73
(Median)
61 Predictive
value of
biomarkers in
adults with CAP
5.8 (30 days)
9.1 (90 days)
11.9 (180 days)
12 (1 year)
Kolditz,
2012 [30]
Germany Prospective
cohort
Hospitalized
adults with CAP
51 72
(Median)
49 Evaluate the
prognosis of
biomarkers for
ICU admission
or mortality
12 (7 days)
Suberviola,
2012 [31]
Spain, 2009 Prospective
cohort
Patients aged
17 yo or above
admitted to ICU
with CAP and
severe sepsis or
septic shock
49 59.4
(Mean)
67.3 Predictive
value of
proADM for
mortality in
patients with
CAP. Compare
the prognostic
value of
biomarkers and
scores.
35 (in-hospital)
Courtais,
2013 [32]
France,
2009e2010
Prospective
cohort
Adults with CAP
presenting to
ED
109 70.5
(Median)
63 Prognostic
value of MR-
proADM in
patients with
8.3 (30-days)
(continued on next page)
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Table 1 (continued )
Author, year Study setting Study design Patient
population
Patients,
n
Age, yr Male, % Aim Mortality, %
CAP presenting
to the ED
Julian-Jimenez,
2013 [33]
Spain,
2011e2012
Prospective
cohort
Patients over
14 yo with CAP
who presented
to an urgent
care facility
127*** 65.8
(Mean)
58.3 Predictive
value of
biomarkers for
short and mid-
term mortality
in patients with
CAP
8.3 (in-
hospital)
10.3 (30-days)
22.6 (180 days)
Lacoma,
2013 [34]
Spain Prospective
cohort
Patients
presenting to
ED with
pneumonia for
which blood
culture was
obtained
85 n.a. 69.4 Correlate
biomarkers
with mortality
risk scores.
(30 days)
CAP, community-acquired pneumonia; ED, emergency department; MR-proADM, midregional proadrenomedullin.
*Same patient cohort; **demographic data included patients with lower respiratory tract infection; *126 analyzed.
1574 R. Cavallazzi et al.with elevated MR-proADM (OR Z 5.0; 95% CI: 3.86e6.49; P
value < 0.001). There was no significant heterogeneity (P
valueZ 0.624). The I2 value was 0%. The sensitivity ranged
from 0.62 to 0.80, while the specificity ranged from 0.53 to
0.86 (see Fig. 6).
Risk of bias
Nine quality items were assessed; more than half of the
studies did not complete 3 of these items. Table 4 and Fig. 7
summarize the findings of risk of bias assessment.Figure 2 Forest plot displaying meta-analysis of the odds rati
midregional proadrenomedullin.Sensitivity analysis
We performed sensitivity analysis for short-term mortality
according to 2 items in which most studies showed a high
risk of bias. The pooled OR was 7.75 (95% CI: 4.72e12.70; P
value < 0.001) in studies that did not establish a test cut-
off a priori [3e5,7,31e34], and 5.27 (95% CI: 3.50e7.92;
P value < 0.001) in the study that established it a priori
[28]. The pooled OR was 7.05 (95% CI 4.13e12.03; P
value < 0.001) in studies that had commercial funding
[4,5,7,28,32,34], and 7.25 (95% CI 3.20e16.42; Po of short-term mortality in patients with increased level of
Figure 3 Forest plots displaying sensitivity and specificity of midregional proadrenomedullin for the prediction of short-term
mortality in patients with community-acquired pneumonia.
Midregional proadrenomedullin 1575value < 0.001) in studies that were free of commercial
funding [3,31,34].Discussion
The main finding of our study is that an increased level of
MR-proADM was associated with an increase in the odds of
both short-term death and the composite outcome of
complications in patients with CAP. The direction of the
measure was consistent across all studies. The relativelyTable 2 Long-term midregional proadrenomedullin prediction o
Author, year Cutoff
(nmol/l)
Estimate
Huang, 2009 [28] 1.45 Subjects in the high
MR-proADM quartile
higher mortality tha
those in the quartlil
e3 (33% vs 14%; P
value < 0.001)
Kruger, 2010 [7] Not available Significant increase
the hazard of death
every one unit incre
in MR-proADM(log10
(HR Z 1.9; 95% CI:
e2.8; P value Z 0.0
Guertler, 2011 [6] 1.97 Significant increase
the hazard of death
patients with MR-
proADM > 1.97 comp
with those with MR-
proADM < 0.83
(HR Z 3.3; 95% CI 1
e6.2; P value < 0.0
Bello, 2012 [4] Not available CURB-65 þ MR-proA
AUC: 0.870 (95% CI:
0.806e0.920); P
value < 0.001
Julian-Jimenez,
2013 [33]
Not available CURB-65 þ MR-proA
AUC: 0.928 (95% CI:
0.855e1.0); P
value < 0.001
PSI þ MR-proADM AU
0.942 (95% CI: 0.899
e0.986); P value < 0
MR-proADM, midregional proadrenomedullin; HR, hazard ratio; CURB
PSI, Pneumonia Severity Index.narrow confidence intervals indicate high precision of the
pooled results. However, the individual studies showed
variation in the accuracy of the test for short-term mor-
tality. The sensitivity of the test, for instance, ranged from
0.46 to 0.92. Two studies with low sensitivity had a low
sample size [31,34], and one of them used a very high test
cut-off [31]. On the other hand, the study by Huang et al.
also showed a low sensitivity in spite of a large sample size
and establishment of the test cut-off a priori [28]. The
specificity of the test was more consistent across the
studies.f mortality in patients with community-acquired pneumonia.
Adjustment Outcome
est
lad
n
e 1
Not available 90-day mortality
in
for
ase
)
1.3
012)
CURB-65, comorbidity 180-day mortality
in
for
ared
.7
01)
gender, chills, age,
comorbidities, and crp
18-month mortality
DM CURB-65 1-year mortality
DM
C:
.001
CURB-65 180-day mortality
-65, confusion, urea, respiratory, blood pressure score, and age;
Table 3 Midregional proadrenomedullin (MR-proADM) and risk score area under the receiver operating characteristic curve
with corresponding 95% CI for the prediction of short-term mortality.
Kruger, 2010a [7] Albrich, 2011b [3] Bello, 2012b [4] Julian-Jimenez, 2013b [33]
Relative increase in AUC with
combined MR-proADM þ risk
score as compared to risk
score alone, estimate (95% CI)
16% (7%e46%) 11% (1%e24%) 6% (2%e14%) 7% (5%e20%)
MR-proADM þ risk score,
estimate (95% CI)
0.85 (0.74e0.96) 0.8 (0.73e0.86) 0.90 (0.853e0.936) 0.934 (0.855e1.0)
Risk score alone, estimate (95% CI) 0.73 (0.6e0.86) 0.72 (0.66e0.77) 0.851 (0.798e0.895) 0.874 (0.804e0.964)
MR-proADM, estimate (95% CI) 0.85 (0.74e0.96) 0.76 (0.68e0.83) 0.859 (0.807e0.902) 0.892 (0.811e0.974)
a CRB-65, confusion, respiratory, blood pressure, and age score.
b CURB-65, confusion, urea, respiratory, blood pressure, and age score.
1576 R. Cavallazzi et al.A clinically relevant question is whether MR-proADM
adds discriminant ability to an established risk score. A
prior meta-analysis by Loke et al. showed a CURB-65 diag-
nostic OR for death of 6.40 [35], an estimate that is similar
to one we found for MR-proADM. This finding supports the
notion that they are both similarly accurate for the pre-
diction of death and could perhaps be used interchange-
ably. However, our analysis also suggests that a better
approach may be the combined use of MR-proADM to CURB-
65/CRB-65 since their association led to improved discrim-
inant ability over that of the risk score alone.
Although the data for long-term prognosis is more scant,
the available evidence also seems to indicate an increased
risk of mortality in patients with CAP presenting with high
level of MR-proADM. In the study by Huang et al., the
analysis of patients with PSI classes IV/V found that pa-
tients in the highest MR-proADM quartile had significantly
higher mortality at 90 days compared with patients whose
MR-proADM levels were in the quartiles 1 to 3. The same didFigure 4 Forest plot of area under the receiver operating ch
drenomedullin over risk score.not hold true for patients with PSI classes I to III, in which
mortality was low and did not significantly change accord-
ing to MR-proADM quartile. Furthermore, the addition of
MR-proADM to clinical prediction rules did not significantly
change the AUC for the prediction of mortality [28]. In the
study with longest outcome ascertainment (18 months), the
hazard of death was 1.9 higher for those with MR-proADM
level between 1.22 and 1.97 nmol/l, and 3.3 higher for
those with MR-proADM level > 1.97 nmol/l compared with
those whose MR-proADM level was <1 nmol/l. The analysis
was statistically significant and was adjusted for a number
of confounders [6]. For the prediction of mortality at 180
days, Julian-Jimenez et al. reported that the AUC of MR-
proADM was higher than that of clinical prediction rules
[33]. In the study by Bello et al., the addition of MR-proADM
to PSI led to significantly better discrimination compared
with PSI alone for the prediction of 1 year mortality [4]. In a
regression analysis with adjustment for CURB-65 and
comorbidities, patients with increase in the MR-aracteristic curve ratio of risk score plus midregional proa-
Figure 5 Forest plot displaying meta-analysis of the odds ratio of short-term complications in patients with increased level of
midregional proadrenomedullin.
Midregional proadrenomedullin 1577proADM(log10) had a 1.9 significant increase in the hazard of
180-day mortality [7].
Risk of bias in the included studies
The 2 items in which most studies showed a high risk of bias
included “establishment of test cut-off a priori” and “being
free of commercial funding”. Our sensitivity analysis
showed the pooled results did not substantially change
when the data are stratified according to these items.
Practical application
Given the value of MR-proADM for the prediction of short-
term mortality in patients with CAP, it is reasonable to
expect that this test will be valuable for the guidance of
hospital admission triage and discharge in these patients,
and will ultimately contribute to decrease in the length of
hospital stay. To test this hypothesis, Albrich et al. per-
formed a proof-of-concept randomized intervention trial in
which triage and discharge decisions for patients with lower
respiratory tract infection were made by the treating
physician with the help of either medical and bio-
psychosocial risk assessment or MR-proADM plus medical
and biopsychosocial risk assessment criteria. The studyFigure 6 Forest plots displaying sensitivity and specificity of m
complications in patients with community-acquired pneumonia.enrolled 313 patients. There was no significant difference
in length of stay between the 2 groups. A limitation of this
trial was that the study algorithm was overruled in 39.3% of
the patients at presentation and in 34.5% during hospitali-
zation [20].Limitations
Our systematic review has some limitations. Only a few
studies reported on long-term term outcomes, and they
described the outcomes in a heterogeneous way. In some
instances of missing information, we were unable to obtain
the data despite an attempt to contact the authors of the
primary studies.Implications for future research
There is need for additional clinical trials evaluating the
integration of MR-proADM– perhaps in association with
other biomarkers– into clinical pathways for risk stratifica-
tion of patients with CAP. A challenge is to obtain adequate
adherence to a proposed clinical pathway. A way of over-
coming this challenge is to carry out pilot phase studies
with the goal of assessing the adherence to protocol.idregional proadrenomedullin for the prediction of short-term
Table 4 Quality items for assessment of risk of bias in the included studies.
Christ-
Crain,2006 [5]
Huang,
2009 [28]
Kruger,
2010 [7]
Guertler,
2011 [6]
Albrich,
2011 [3]
Bereciartua
Urbieta,
2011 [29]
Bello,
2012 [4]
Kolditz,
2012 [30]
Suberviola,
2012 [31]
Courtais,
2013 [32]
Julian-Jimenez
2013 [33]
Lacoma,
2013 [34]
Demographic
characteristic
fully described
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Were selection
criteria clearly
described?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Definition of CAP
well described
Yes Yes Yes Yes No Yes Yes Yes Yes Yes Yes Yes
Was the index
test obtained
early in course
of disease?
Unclear Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Was the execution
of the index
test described
in sufficient
detail to permit
replication of
the test?
Yes Yes Yes No Yes Yes Yes No Yes Yes Yes No
Were withdrawals
from the study
explained?
Unclear Yes Yes Yes Unclear Yes Yes Yes Unclear Yes Yes Yes
Were cut-off values
established
before the study
was started?
No Yes No Yes No No No No No No No No
Were objectives
pre-specified?
Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
Mid and long eterm
follow up
No Yes Yes Yes No No Yes No No No Yes No
Was the study free
of commercial
funding?
No No No Yes Yes No No No Yes No Yes No
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Figure 7 Risk of bias assessment of the studies included in this review.
Midregional proadrenomedullin 1579Complex pathways with low adherence can thus be
simplified before they are tested in clinical trials.
Conclusion
Our review confirms that MR-proADM is associated with
short-term mortality and complications in patients with
CAP. Although the data are not nearly as robust, it also
appears the MR-proADM is valuable for long-term prognosis
of these patients. The combined use of MR-proADM and
CURB-65/CRB-65 provides improved discriminant ability
over the risk score alone. Whether the use of MR-proADM
will translate into better patient outcomes is yet to be
established.
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